CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program

项目摘要 癌症基因发现和癌症生物学博士后研究培训计划的目标， 冷泉港实验室（CSHL）是准备下一代癌症生物学家追求 将癌症基因发现与功能生物学相结合的独立研究职业，以促进 开发和应用新型癌症治疗、诊断和/或预防策略。 这个为期三年的研究培训计划的特点包括：强制性和选修性相结合 教学课程和研讨会;结构化职业发展指导;基于研究生和社区的 教学选择;和实验室的研究经验，在我们的CSH，NCI指定的整合 癌症中心 癌症研究机会跨越高度综合的领域，包括：1）癌症遗传学-遗传和 癌症的表观遗传进展;癌症诊断和实验技术开发 （CRISPR/Cas，单细胞分析）; 2）癌症基因调控和细胞增殖-剪接，RNA 生物学、复制、核结构、转录、肿瘤生长和转移; 3）癌症信号 转导-药物敏感性和耐药性、肿瘤微环境和转移、免疫反应; 和4）数量生物学-群体遗传学、基因组结构和进化。 博士后学员受益于：强大的教师与学员比例;协作和多学科 研究环境;内部执行委员会，包括学员代表和 独立的外部咨询委员会;现场国际知名的科学会议和课程 计划;新扩大的国家的最先进的癌症研究设施;加强接触翻译 肿瘤学作为与Northwell Health的新机构合作伙伴关系的一部分。 在过去五年中，大约有74名受训人员从该方案中受益，其中7名 培训生（每年3名）得到了NCI T32奖的支持，另有2名培训生得到了支持 由联合纽约州匹配和CSHL机构资助。CSHL提交了一份竞争性的T32 2015年的续约申请要求四个职位，这些职位未能获得新的NCI资金。 评论家认为该计划的整体影响很高，但指出了几点和建议。所有 我们已仔细评估有关建议，并在今次重新提交的文件中加以处理。程序增强 包括：为学员提供更多机会，了解癌症的临床影响， 获得在进行和参与临床研究所涉及的复杂性的升值; T32 培训生的具体活动，包括向公众传播科学的培训;以及获得知识 人口多样性在癌症健康差异研究中的重要性。选修课程有 更新和新的方法，以进一步提高计划申请人和参与者的多样性 已经开始了

Project Summary The objective of the Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program at Cold Spring Harbor Laboratory (CSHL) is to prepare the next generation of cancer biologists to pursue independent research careers integrating cancer gene discovery with functional biology in order to facilitate the development and application of novel cancer therapeutic, diagnostic and/or preventive strategies. Features of this three-year research training program include: a combination of mandatory and elective didactic courses and seminars; structured career development guidance; graduate and community-based teaching options; and research experiences in laboratories integrated within our CSH, NCI designated Cancer Center. Cancer research opportunities span highly integrated areas that include; 1) Cancer Genetics - genetic and epigenetic progression of cancer; cancer diagnostics and experimental technology development (CRISPR/Cas, single cell analysis); 2) Cancer Gene Regulation and Cell Proliferation - splicing, RNA biology, replication, nuclear structure, transcription, tumor growth and metastasis; 3) Cancer Signal Transduction - drug sensitivity and resistance, tumor microenvironment and metastasis, immune response; and 4) Quantitative Biology- population genetics, genome structure and evolution. Postdoctoral trainees benefit from: a strong faculty to trainee ratio; a collaborative and multidisciplinary research environment; an internal Executive Committee that includes trainee representatives and an independent External Advisory Board; an on-site internationally renowned Scientific Meetings and Courses program; newly expanded state-of-the-art cancer research facilities; enhanced exposure to translational oncology as part of a new institutional partnership with Northwell Health. Over the past five years, approximately seventy-four trainees benefited from the program, of which seven trainees (three per year) were supported by the NCI T32 award, with two additional trainees being supported by combined New York State matching and CSHL institutional funding. CSHL submitted a competing T32 renewal application in 2015 requesting four positions that fell short of securing renewed NCI funding. Reviewers found the program's overall impact to be high, but noted several points and recommendations. All suggestions have been carefully evaluated and addressed in this resubmission. Program enhancements include: providing trainees with additional opportunities to understand the clinical impact of cancer and to gain an appreciation of the complexities involved in conducting and participating in clinical research; T32 trainee specific events that include training in Communicating Science to the Public; and gaining knowledge about the importance of population diversity in cancer health disparities research. Elective courses have been updated and new approaches to further enhance the diversity of program applicants and participants have begun.